ngram’s Post

We all know that the AI revolution is coming!  However, the implications on the work of pharmaceutical market research and brand strategy consulting businesses are still unclear. In a recent webinar, titled ‘Why AI chatbots will definitely replace the pharmaceutical insights agency’, Branding Science's Nick Ross (Senior Director, Client Services) and Gabriel Musker (Data Scientist) built a pitch for a purely AI insights agency (brAInsight) to compete in tomorrow’s market, without a discussion guide in sight. Click here to take a look at our latest article and find out what they had to say: https://lnkd.in/egh-5Z-r #AI #Pharma #Webinar

In pharmaceutical and medical market research, accuracy in transcription and analysis is essential. SurveyMind ensures that every complex term - from 'Pharmacogenomics' to 'Cytokine Storms' - is transcribed with precision. With our GDRP-compliant platform, you can transform hours of audio into text rapidly, freeing up valuable time. A top pharma company recently used SurveyMind for a critical project and commented: 'Wow, I wish I found SurveyMind 10 years ago....' Visit surveymind.io for more info or to start your free trial. #MedicalTranscription #PharmaInnovation #AI #HealthTech

As analysts forecast a staggering surge in business spending on AI, projected to reach a whopping $300 billion by 2026, it's evident that the transformative power of AI is poised to reshape industries far and wide. Among the sectors primed for significant disruption, healthcare and the pharmaceutical industry stand out as frontrunners, with AI heralding a new era of innovation and efficiency. For more information, click here: https://bit.ly/3xhjF7U #PharmaTimes #AI #Healthcare #PharmaIndustry

As analysts forecast a staggering surge in business spending on AI, projected to reach a whopping $300 billion by 2026, it's evident that the transformative power of AI is poised to reshape industries far and wide. Among the sectors primed for significant disruption, healthcare and the pharmaceutical industry stand out as frontrunners, with AI heralding a new era of innovation and efficiency. For more information, click here: https://bit.ly/3xhjF7U #PharmaTimes #AI #Healthcare #PharmaIndustry

What level of ROI can #biopharma companies expect to achieve from R&D? Unleash AI’s potential - the 14th edition of our annual R&D ROI report is now live and explores returns for 20 leading biopharma companies, the implications of #AI on the industry and what #Pharma leaders should consider to improve #ClinicalTrials. Read the report for insights in full ➡️ https://deloi.tt/3yoDuuI #LifeSciences

What are they key take-aways from our latest Deloitte study on ROI in #pharma R&D? 💡 Productivity Trends 👉 Our analysis over the past 14 years shows a decline in productivity from 2010 to 2019, followed by a short-lived improvement due to COVID-19 in 2020-21, and a dip in 2022. However, our latest modeling shows signs of improvement with an IRR of 4.1%, up from 1.2% last year. The total reported R&D spend by our cohort has increased, reflecting an expanded range of assets. The cohort's average forecast peak sales per pipeline asset fell, but the total revenue for our cohort with reported top 20 pharma R&D sales increased by 9.6% in 2023. 💡Challenges and Opportunities for R&D 👉 Regulatory changes, the impending loss of exclusivity of high-value assets, inflationary pressures, and rising protocol design complexity are putting pressure on the R&D operating model. However, they also create opportunities for improvement through #AI-enabled digital transformation. 💡Disruption in the #Biopharma Industry 👉The #biopharma industry is on the brink of disruption driven by interoperable data, advances in AI and analytics, open and secure platforms, and patient-centric care. These have the potential to deliver less costly and more productive drug development. 💡Potential of #AI in0 #Biopharma 👉 If #biopharma capitalizes on #AI's potential, it could reverse the decline in the IRR of biopharma innovation and enable the industry to thrive.

The pharmaceutical and healthcare industry faces significant pressure! 💥 While rising lifetime values of drugs are lucrative, the industry faces critical challenges like skilled labor shortages, sensitive global supply chains, and intense global competition. 💡The hidden trump card? This industry is sitting on a goldmine of data, ideally positioning it to leverage AI's power. Yet, a pressing question looms: Why hasn't AI fully penetrated the pharmaceutical landscape? This post sheds light on some key insights! To delve deeper, explore our whitepaper: https://lnkd.in/dHDqU2Yu #pharma #ai #aiadvantage #data

Resilience is a major strategic priority for pharma supply chains. With many pharmaceutical companies increasingly aware of blind spots in their supply chains, greater visibility to see and predict potential disruptions will be key to success. See how digital tools, AI and data analytics can propel pharma supply chains into the future with Olaf Zweig and Derron Stark's latest insights. Read here: https://lnkd.in/eAhi8R5g #pharma #supplychains #supplychainvisibility #AI

Who’s posting what? Artificial Intelligence related social media posts increased by 32% in the pharma industry in Q1 2023 Artificial Intelligence is among the top emerging technologies being employed for drug discovery and development and has demonstrated strong potential in the pharmaceutical sector. GlobalData’s Artificial Intelligence (AI) in Drug Discovery Market: Thematic Research Report provides a detailed understanding of key trends, industry analysis, and AI specialists in drug discovery. Read more: https://lnkd.in/dqs-UrJG #artificialintelligence #drugdiscovery #pharmaceuticaltechnology #globaldata